Substantially pure diastereoisomers of tetrahydrofolate derivatives

  • US 6,500,829 B1
  • Filed: 04/18/1995
  • Issued: 12/31/2002
  • Est. Priority Date: 09/03/1986
  • Status: Expired due to Term
First Claim
Patent Images

1. A pharmaceutical composition for therapeutic use which consists essentially of a therapeutically effective amount sufficient for the treatment of human beings for methotrexate rescue or folate deficiency, of a pharmaceutically acceptable compound which is a (6S) diastereoisomer selected from the group consisting of (6S) leucovorin (5-formyl-(6S)-tetrahydrofolic acid) and pharmaceutically acceptable salts and esters of (6S) leucovorin;

  • wherein the compound consists of a mixture of (6S) and (6R) diastereoisomers and consists of at least 92% by weight of the (6S) diastereoisomer, the balance of said compound consisting of the (6R) diastereoisomer;

    in combination with a pharmaceutically acceptable carrier.

View all claims
  • 1 Assignment
Timeline View
Assignment View